Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on October 21, 2019. The report details a material definitive agreement and unregistered equity sales involving the Company and its wholly-owned subsidiary, NeuroClear Technologies, Inc.
Key Financial Metrics
- Transaction Type: Private placement of common stock by NeuroClear Technologies, Inc.
- Shares Sold: 82,200 shares of NeuroClear common stock.
- Price Per Share: $8.35.
- Total Consideration: $686,370.
- Maximum Offering Size: Up to $20,000,000 under the Purchase Agreement.
- Reporting Period: The filing text does not provide standard revenue, profit, cash flow, or debt metrics as this is a current report on a specific event, not a periodic financial statement.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with accredited investors. Key terms include:
- Closing Date: October 21, 2019.
- Share Exchange Provision: If NeuroClear stock is not listed on a national securities exchange by October 31, 2020, or if a change of control occurs earlier, investors may exchange each NeuroClear share for 1.1 shares of BioSig Technologies, Inc. common stock.
- Extension: The offering period may be extended to November 30, 2019, with written notice.
- Regulatory Status: The offering relies on exemptions under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Outlook, Risks, and Contingencies
The filing highlights specific contingencies tied to the Share Exchange provision:
- Listing Risk: The exchange of shares is contingent on NeuroClear failing to list its stock on a national securities exchange by the October 31, 2020 deadline.
- Dilution Risk: The 1.1 exchange ratio could result in dilution to existing BioSig shareholders if the exchange is triggered.
- Management Commentary: The filing text does not provide additional management commentary or forward-looking guidance beyond the terms of the agreement.
Investor Verification Checklist
- Verify the exact number of shares issued in subsequent closings under the $20,000,000 cap.
- Monitor NeuroClear Technologies' progress toward listing on a national securities exchange by October 31, 2020.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants.
- Confirm the identity of the accredited investors involved in the initial $686,370 closing.